• WKN: 746100
  • ISIN: DE0007461006
  • Land: Deutschland

Nachricht vom 10.08.2018 | 08:00

PVA TePla AG: Publication of 2018 half-year report

DGAP-News: PVA TePla AG / Key word(s): Half Year Results

10.08.2018 / 08:00
The issuer is solely responsible for the content of this announcement.

PVA TePla: Publication of 2018 half-year report

- Sales revenue/EBITDA in line with planning

- Incoming orders of EUR 76.5 million (up 68%)

- Order backlog of EUR 171.1 million (230%)

- Forecast for year confirmed: Sales revenue of EUR 94 million, EBITDA of EUR 11 million

The PVA TePla Group, Wettenberg, a manufacturer of systems for the production of industrial crystals, vacuum and high-temperature systems, plasma systems and systems for non-destructive quality inspection, generated consolidated revenue of EUR 38.2 million (previous year: EUR 43.6 million) and EBITDA of EUR 2.0 million (previous year: EUR 2.6 million) in the first half of 2018. It should be noted as regards revenue recognition in the first half of 2018 that the new IFRS 15 no longer allows the recognition of some revenue from ongoing contracts to the original extent. Had the previous accounting requirements of IAS 11 and IAS 18 been applied as of June 30, the PVA TePla AG would have recognized a further EUR 5.4 million in revenue and an additional EBITDA of EUR 1.5 million.

Incoming orders and order backlog
Incoming grew significantly year-on-year to EUR 76.5 million as of June 30, 2018 (EUR 45.6 million). Both Industrial Systems and Semiconductor Systems contributed to the increase in incoming orders. In particular, the crystal growing systems business unit again performed very well and accounted for 50% of total order intake in the Semiconductor Systems division. Orders in the ultrasound measuring systems business unit were almost 50% higher than in the same period of the previous. The book-to-bill ratio is 2.00 (previous year: 1.05). The order backlog more than tripled year-on-year to EUR 171.1 million as of June 30, 2018 (EUR 51.7 million).

The operating cash flow amounted to EUR -12.6 million in the first six months of 2018 (H1 2017 [previous year]: EUR 10.2 million). This includes EUR 6 million in cash and cash equivalents that were invested in short-term investments and are not reported as cash equivalents. In addition, the PVA TePla Group received significant advance payments for major orders in fiscal 2017. These payments are now gradually being used for the production of these systems. The net financial position (cash and cash equivalents less current and non-current financial liabilities) was EUR 15.9 million (previous year: EUR 0.8 million).

Outlook for fiscal 2018
The Management Board is forecasting consolidated revenue in the scale of EUR 94 million for the current fiscal year with EBITDA in the scale of EUR 11.0 million.

The half-year report is now available to download on the company's website www.pvatepla.com.

For further information, please contact:

Dr. Gert Fisahn
Investor Relations
Tel: +49(0)641/68690-400

10.08.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this


UniDevice AG: Rekord-Ergebnis in 2018

Nach starkem Schlussspurt hat die UniDevice AG in 2018 Umsatz und Ergebnis deutlich gesteigert. Der B2B-Broker für hochpreisige Smartphones sollte auch künftig eine hohe Nachfrage verzeichnen und von der Ausnutzung unterschiedlicher Preisniveaus in den verschiedenen Ländern profitieren. Der Umsatz soll 2019 auf mindestens 380 Mio. € und in 2020 auf mindestens 410 Mio. € ansteigen, nachdem 2018 317 Mio. € erreicht wurden. Bei einem ermittelten Kursziel in Höhe von 2,35 € lautet das Rating KAUFEN.

News im Fokus

Fresenius Medical Care veröffentlicht Form 20-F für das Geschäftsjahr 2018

21. Februar 2019, 11:51

Aktueller Webcast

Ströer SE & Co. KGaA

Vorläufige Geschäftszahlen 2018

26. Februar 2019

Aktuelle Research-Studie

Sanochemia Pharmazeutika AG

Original-Research: Sanochemia Pharmazeutika AG (von Sphene Capital GmbH): Buy

21. Februar 2019